Day One Bio Day One Bio

Scientific Publications

Contributing to and advancing the scientific dialogue.

December 2024

Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

Nysom K, Kilburn LB, Leary SES, Landi DB, de Vos-Kerkhof E, Perreault S, Witt O, Ziegler DS, Hernáiz Driever P, Franson AT, Baxter PA, Whipple NS, Kline C, Segal D, Jabado N, Bailey S, McCowage G, Hansford JR, Khuong-Quang D-A, Gottardo NG, Hassall TE, Han JW, Oren MY, Chi SN, Qiu J, Da Costa D, Govinda Raju S, Manley P, Hargrave D. Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial [published online ahead of print December 19, 2024]. NeuroOncol. 2024.

November 2024

Type II RAF inhibitor tovorafenib in relapsed/refractory (r/r) pediatric low-grade glioma (pLGG): Results from patients on a drug holiday (DH) in the phase 2 FIREFLY-1 trial.

Perreault S, Khuong-Quang D-A, Kilburn LB, Landi DB, Leary SES, Bailey S, Larouche V, Nysom K, Hernáiz Driever P, Baxter PA, Witt O, Yalon Oren M, Abdelbaki MS, Kline C, Whipple NS, Ziegler DS, van der Lugt J, Hassall TE, Gerber NU, Segal D, Hansford JR, McCowage G, Kang HJ, Han JW, Hargrave DH, Franson AT, Toledano H, Jabado N, Gottardo NG, Chi SN, Oren L, Tan EEK, Mueller S, Hoke ME, Kim Y, Walter A, Da Costa D, Manley P, Waanders AJ. CTNI-09. Type II RAF inhibitor tovorafenib in relapsed/refractory (r/r) pediatric low-grade glioma (pLGG): Results from patients on a drug holiday (DH) in the phase 2 FIREFLY-1 trial. Poster presentation at: 29th Annual Meeting and Education Day of the Society for Neuro-Oncology; November 22, 2024; Houston, TX.

November 2024

Health-related Quality of Life (HRQOL) in the phase 2 FIREFLY-1 (PNOC026) trial of the type II RAF inhibitor tovorafenib in relapsed/refractory (r/r) pediatric low-grade glioma (pLGG).

Peipert J(D), Baxter PA, Yu S, Oestreicher N, Zelt S, Hernáiz Driever P, Bailey S, McCowage G, Ziegler DS, Witt O, Kang HJ, Hassall TE, Han JW, Franson AT, Yalon Oren M, Toledano H, Larouche V, Abdelbaki MS, Jabado N, Gottardo NG, Gerber NU, Whipple NS, Segal D, Chi SN, Oren L, Tan EK, Mueller S, Kilburn LB, Nysom K, Khuong-Quang D-A, Landi DB, van der Lugt J, Leary SES, Perreault S, Waanders AJ, Hargrave D, Kline C, McKenna C, Manley P, Govinda Raju S, Hansford JR. NCOG-05. Health-related Quality of Life (HRQOL) in the phase 2 FIREFLY-1 (PNOC026) trial of the type II RAF inhibitor tovorafenib in relapsed/refractory (r/r) pediatric low-grade glioma (pLGG). Poster and 4-minute rapid report oral presentation at: 29th Annual Meeting and Education Day of the Society for Neuro-Oncology; November 22, 2024; Houston, TX.

September 2024

Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory (R/R) Melanoma or Other Solid Tumors with RAF Fusions and/or RAF1 Amplification.

Vieito M, Garralda Cabanas E, Mehmi I, Gaudy-Marqueste C, O’Neil BH, Medina TM, Body Arance A, Kummar S, Najjar YG, Bedard PL, Chu C, McKenna C, Hume S, Kopp LM, Lee J. 614MO – Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory (R/R) Melanoma or Other Solid Tumors with RAF Fusions and/or RAF1 Amplification. Mini oral presentation at: ESMO Congress 2024; September 14, 2024; Barcelona, Spain.

June 2024

Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial.

Kline C, Waanders AJ, Ziegler DS, Kilburn LB, Nysom K, van der Lugt J, Hassall TE, Gerber NU, Segal D, Larouche V, Khuong-Quang D-A, Hansford JR, Leary SES, Hernáiz Driever P, Bailey S, Perreault S, McCowage G, Witt O, Baxter PA, Kang HJ, Han JW, Hargrave D, Franson AT, Yalon Oren M, Toledano H, Abdelbaki MS, Jabado N, Gottardo NG, Whipple NS, Chi, Oren L, Tan EEK, Mueller S, Wright KD, Blackman SC, Qiu J, Podesta D, Walter A, Da Costa D, Manley P, McLeod L, Landi DB. LGG-40. Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial. Oral presentation at: 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024); June 30, 2024; Philadelphia, PA.

June 2024

Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial

Kline C, Waanders AJ, Ziegler DS, Kilburn LB, Nysom K, van der Lugt J, Hassall TE, Gerber NU, Segal D, Larouche V, Mueller S, Walter A, Manley P, McLeod L, Landi DB. Abstract 10036. Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial. Poster presentation at: 2024 ASCO (American Society for Clinical Oncology) Annual Meeting; June 1, 2024; Chicago, IL & Virtual.

April 2024

Disease burden and healthcare utilization in pediatric low-grade glioma: a United States retrospective study of linked claims and electronic health records

Zelt S, Cooney T, Yu S, Daral S, Krebs B, Markan R, Manley P, Kieran M, Govinda Raju S. Disease burden and healthcare utilization in pediatric low-grade glioma: a United States retrospective study of linked claims and electronic health records [published online ahead of print April 27, 2024]. Neuro-Oncol Pract. 2024.

April 2024

Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation

Rastogi S, Perino S, Lal-Nag M, Wang Y, Blackman SC, Venetsanakos E. 1972. Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation. Poster presentation at: AACR (American Association for Cancer Research) Annual Meeting 2024; April 8, 2023; San Diego, CA.

See our progress in motion.

See open jobs

You are now leaving the Day One Biopharmaceuticals Corporate Website

You will now be redirected to the requested website. Please confirm that you want to proceed.

Yes No